Abeona Therapeutics Inc.

NASDAQ:ABEO

Biotechnology

Healthcare
$2.73 +1.06%

+$0.06 today

Market cap
$156.01M
Beta
1.35
P/E (TTM)
4.9
EPS (TTM)
$1.17
52W Low $4.00High $7.54

Volume 1.71M

Average 1.12M

ABEO Long-term Debt

Borrowings due after more than one year.

Abeona Therapeutics Inc.NASDAQ: ABEO

Long-term Debt · Q1 FY2026 · quarter ended Mar 2026

Long-term debt falls 57.3% from a year ago

Long-term debt stood at $4.75M at the end of Q1 FY2026, down 57.3% from a year earlier and down 39.2% from the prior quarter.

Context

  • Long-term debt amounted to 2.4% of total assets at the end of Q1 FY2026, down 8.8 pp from a year earlier.
  • Long-term debt increased in 1 of the last 3 fiscal years.

What to watch

Whether long-term debt keeps falling in the next quarterly balance sheet after a -57.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterMar 2026
$4.75M-39.2% QoQ
Last fiscal yearDec 2025
$7.81M-40.1% YoY
Year agoMar 2025
$11.14M-57.3% since
Long-term Debt past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-57.3%——
1 year-40.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Long-term Debt history

USD · from the balance sheet

Latest · FY2025
7.81M USD
Year-over-year change
-40.1%

Long-term Debt vs competitors

How ABEO compares with its peers on the latest reported figures

  • ABEO's Mar 2026 long-term debt of $4.75M is the 3rd highest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of -57.3% is the 3rd highest of 4, against a peer median of -44.5%.
  • Long-term debt amounts to 2.4% of total assets for ABEO, versus a peer median of 0.0%.
ABEO Competitors Peer median
Long-term Debt for ABEO and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
HUMAHumacyte, Inc.Mar 2026$35.87M -44.5%+20.3%32.4%
ARCTArcturus Therapeutics Holdings Inc.Mar 2026$19.68M +31.2%—8.0%
ABEOAbeona Therapeutics Inc.Mar 2026$4.75M -57.3%—2.4%
ASMBAssembly Biosciences, Inc.Mar 2026$1.9M ——0.8%
PBYIPuma Biotechnology, Inc.Mar 2026$0 -100.0%-63.7%0.0%
SGMTSagimet Biosciences Inc.Mar 2026$0 ——0.0%
ELDNEledon Pharmaceuticals, Inc.Mar 2026$0 ——0.0%
FHTXFoghorn Therapeutics Inc.Mar 2026$0 ——0.0%
VYGRVoyager Therapeutics, Inc.Mar 2026$0 ——0.0%
TNYATenaya Therapeutics, Inc.Mar 2026$0 ——0.0%
Peer median (excluding ABEO) $0-44.5%-21.7%0.0%

Competitors are the stored peer set for ABEO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents32.94M14.22M14.47M23.36M78.44M
Short-term Investments12.09M37.93M37.75M74.36M112.97M
Net Receivables3M188K2.44M1.65M6.72M
Inventory00005.49M
Other Current Assets891K762K338K1.48M1.29M
Total Current Assets56.29M53.1M55.74M100.85M204.91M
Property, Plant & Equipment (Net)21.74M11.07M7.99M7.98M13.88M
Goodwill00000
Intangible Assets1.38M0000
Long-term Investments00000
Tax Assets00000
Other Non-current Assets168K43K277K96K781K
Total Non-current Assets23.29M11.12M8.27M8.08M14.66M
Total Assets79.59M64.21M64M108.93M219.57M
Account Payables4.33M1.81M1.86M3.44M7.89M
Short-term Debt0005.93M12.22M
Tax Payables00000
Deferred Revenue296K0000
Other Current Liabilities1.79M2.8M3.69M4.46M5.64M
Total Current Liabilities16.62M7.78M13.42M16.59M29.57M
Long-term Debt00013.04M7.81M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities13.04M23.82M31.35M32.01M18.9M
Total Non-current Liabilities20.6M29.67M35.75M48.31M30.78M
Total Liabilities37.22M37.45M49.18M64.9M60.35M
Common Stock1.47M177K265K457K550K
Retained Earnings(655.64M)(695.34M)(749.52M)(813.26M)(742.08M)
Accumulated OCI(27K)(129K)(66K)8K138K
Other Stockholders Equity00000
Minority Interest00000
Total Equity42.37M26.76M14.83M44.03M159.22M
Total Debt9.38M7.63M5.4M23.05M24.97M
Net Debt(23.56M)(6.59M)(9.07M)(309K)(53.47M)

Abeona Therapeutics Inc.

NASDAQ:ABEO

Intrinsic Alpha fair value

Locked

Current Price

$2.73

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.